Genomics and COVID-19 Vaccine Adverse Events

Recruiting now

Conditions studied: Vaccine Adverse Reaction

In brief

Vaccines routinely used are extremely safe; however, severe adverse events to vaccines do occur. As vaccination against COVID-19 has begun, adverse events to the vaccine, particularly Guillain-Barré syndrome (GBS), vaccine-induced immune thrombotic thrombocytopenia (VITT)/thrombosis with thrombocytopenia syndrome (TTS), and myocarditis/pericarditis, after COVID-19 vaccination have been reported worldwide. Study hypothesis: there are genetic factors that contribute to increased risks of particular COVID-19 vaccine-induced adverse events. The objective of the study is to determine if there are specific genetic factors strongly associated with each of the COVID-19 vaccine-induced adverse events (i.e., GBS, VITT/TTS, and myocarditis/pericarditis).

Key facts

Study ID

NCT05212792

Run by

University of British Columbia

People needed

6325

Starts

2022-06-24

Expected to finish

2026-12-01

Last updated by the study team

2026-05-01

Who can join

Age: 5 and older, up to 99. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Case: Any patient who received COVID-19 vaccines and developed GBS, VITT/TTS, or myocarditis/pericarditis after vaccination
• Control: Any participant who received COVID-19 vaccines and does not experience GBS, VITT/TTS, or myocarditis/pericarditis.

You may not qualify if…

• Individuals who have not received a COVID-19 vaccine
• Individuals who are unable to provide informed consent

Where it is running

• British Columbia Children's Hospital Research Institute — Vancouver, British Columbia, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.